Adil Javed to Magnetic Resonance Imaging
This is a "connection" page, showing publications Adil Javed has written about Magnetic Resonance Imaging.
Connection Strength
0.954
-
Validation of retroactively derived T1 relaxation values from 3D T1-weighted images with clinical and MRI measures of disability in multiple sclerosis. PLoS One. 2025; 20(5):e0323898.
Score: 0.394
-
T1 mapping from routine 3D T1-weighted inversion recovery sequences in clinical practice: comparison against reference inversion recovery fast field echo T1 scans and feasibility in multiple sclerosis. Neuroradiology. 2024 Oct; 66(10):1709-1719.
Score: 0.370
-
Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica. J Neuroophthalmol. 2012 Jun; 32(2):150-3.
Score: 0.040
-
Multiple sclerosis. Part 2: ophthalmic issues in MS therapy. Curr Opin Ophthalmol. 2009 Nov; 20(6):476-81.
Score: 0.034
-
Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis. Mult Scler. 2008 Jul; 14(6):809-14.
Score: 0.031
-
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
Score: 0.021
-
Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches. PLoS One. 2022; 17(9):e0274778.
Score: 0.020
-
Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment. PLoS One. 2018; 13(12):e0209326.
Score: 0.016
-
A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. Mult Scler. 2019 05; 25(6):811-818.
Score: 0.015
-
Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS One. 2017; 12(4):e0173299.
Score: 0.014